Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat.

scientific article published on April 2011

Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1582-4934.2010.01045.X
P932PMC publication ID3922665
P698PubMed publication ID20193037
P5875ResearchGate publication ID41655172

P50authorLing YangQ89474643
P2093author name stringYan Chen
Ling Yang
Zhenzhen Wang
Gen-Sheng Feng
Yi Pan
Yixuan Zhang
Zhenghu Li
Xiangbo Ruan
P2860cites workIdentification and importance of brown adipose tissue in adult humansQ24632425
AMPK and PPARdelta agonists are exercise mimeticsQ24652674
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1Q28131760
Obesity and the risk of heart failureQ28216583
Transcriptional control of brown fat determination by PRDM16Q28593210
Cold-activated brown adipose tissue in healthy menQ29547382
Brown adipose tissue: function and physiological significanceQ29547448
Functional brown adipose tissue in healthy adultsQ29547687
Mechanisms linking obesity to insulin resistance and type 2 diabetesQ29614887
Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men.Q31887210
High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylationQ33782094
Insulin resistance and cardiovascular diseaseQ34011027
The obesity epidemic, metabolic syndrome and future prevention strategiesQ34323455
New methods for calculating metabolic rate with special reference to protein metabolismQ34351677
Mechanisms linking obesity with cardiovascular diseaseQ34590832
Atheroprotective effects of high-density lipoproteinsQ34987979
Metabolic syndrome: a clinical and molecular perspectiveQ36014668
HDL as a target in the treatment of atherosclerotic cardiovascular diseaseQ36058450
Apolipoprotein A-I mimetic peptidesQ36098714
Respiration uncoupling and metabolism in the control of energy expenditureQ36118740
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patientsQ36662681
L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese miceQ36745004
Effect of obesity on high-density lipoprotein metabolismQ37058273
Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclassesQ37370951
Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolismQ40105268
Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.Q41275648
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.Q41759689
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterolQ43862770
The disease burden associated with overweight and obesityQ44817527
Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunitQ45032346
Synthetic peptide analogs of apolipoproteinsQ45187676
D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western dietQ46675074
Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritisQ46705057
An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasmaQ46868439
Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesityQ47902556
Obesity and lipoprotein cholesterol in the Framingham offspring study.Q52755652
Long-Term Treatment with the Apolipoprotein A1 Mimetic Peptide Increases Antioxidants and Vascular Repair in Type I Diabetic RatsQ60684945
Beta-adrenergic, cAMP-mediated stimulation of proliferation of brown fat cells in primary culture. Mediation via beta 1 but not via beta 3 adrenoceptorsQ67879410
Apolipoprotein A-I as a marker of angiographically assessed coronary-artery diseaseQ70442465
Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal womenQ77647860
Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin miceQ80317215
Apolipoprotein A-I mimetic peptidesQ82957586
P433issue4
P921main subjectobesityQ12174
P304page(s)763-772
P577publication date2011-04-01
P1433published inJournal of Cellular and Molecular MedicineQ1524063
P1476titleApolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat.
P478volume15

Reverse relations

cites work (P2860)
Q35926657ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice
Q43160205ApoA-I Milano stimulates lipolysis in adipose cells independently of cAMP/PKA activation
Q61800652Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle
Q35172781Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice
Q92422017Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
Q36593117Brown adipose tissue and its modulation by a mitochondria-targeted peptide in rat burn injury-induced hypermetabolism
Q42252464CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice
Q27000421Cardioprotective functions of HDLs
Q37394438Changes in triglycerides and high-density lipoprotein cholesterol may precede peripheral insulin resistance, with 2-h insulin partially mediating this unidirectional relationship: a prospective cohort study
Q38313076Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
Q92949881Effects of obesity on cholesterol metabolism and its implications for healthy ageing
Q37590250HDL and cholesterol: life after the divorce?
Q38293471HDLs, diabetes, and metabolic syndrome
Q34565254High density lipoprotein: it's not just about lipid transport anymore
Q37603213High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation
Q37642841High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice
Q64277669Human ApoA-I Overexpression Enhances Macrophage-Specific Reverse Cholesterol Transport but Fails to Prevent Inherited Diabesity in Mice
Q48726745In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes.
Q37331224Influence of apolipoproteins on the association between lipids and insulin sensitivity: a cross-sectional analysis of the RISC Study
Q92016771Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis
Q34299607Low high-density lipoprotein cholesterol level is a significant risk factor for development of type 2 diabetes: Data from the Hawaii-Los Angeles-Hiroshima study
Q37614469Modulation of adipose tissue lipolysis and body weight by high-density lipoproteins in mice
Q35267682New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma
Q36406480Novel biological functions of high-density lipoprotein cholesterol
Q33755805Overexpression of apolipoprotein A-I alleviates endoplasmic reticulum stress in hepatocytes
Q64227581Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status
Q26859684Regulation of adipocyte autophagy--the potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I
Q37076473Regulation of signal transduction by HDL.
Q27000047Research advances at the Institute for Nutritional Sciences at Shanghai, China
Q38553529Targeting inflammation in metabolic syndrome.
Q37978209The emerging role of HDL in glucose metabolism
Q28069220The unsolved mystery of apoA-I recycling in adipocyte
Q86542655[Concept of reconstructive body shaping in obesity. Evidence-based therapy algorithm]